0001140361-23-029888.txt : 20230614 0001140361-23-029888.hdr.sgml : 20230614 20230614182715 ACCESSION NUMBER: 0001140361-23-029888 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230613 FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Providenti Anthony C. Jr. CENTRAL INDEX KEY: 0001765583 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22427 FILM NUMBER: 231015462 MAIL ADDRESS: STREET 1: 3760 ROCKY MOUNTAIN AVENUE CITY: LOVELAND STATE: CO ZIP: 80538 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HESKA CORP CENTRAL INDEX KEY: 0001038133 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 770192527 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3760 ROCKY MOUNTAIN AVENUE CITY: LOVELAND STATE: CO ZIP: 80538 BUSINESS PHONE: 9704937272 MAIL ADDRESS: STREET 1: 3760 ROCKY MOUNTAIN AVENUE CITY: LOVELAND STATE: CO ZIP: 80538 4 1 form4.xml X0407 4 2023-06-13 true 0001038133 HESKA CORP HSKA 0001765583 Providenti Anthony C. Jr. 3760 ROCKY MOUNTAIN AVENUE LOVELAND CO 80538 true EVP, Corporate Development false Common Stock 2023-06-13 4 A 0 44456 0 A 63571 D Common Stock 2023-06-13 4 A 0 4056 0 A 67627 D Common Stock 2023-06-13 4 D 0 67627 120 D 0 D Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, these shares of performance-based restricted stock of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger. Includes 396 shares of common stock of the Issuer purchased under the Issuer's employee stock purchase plan on May 26, 2023 and 11,000 shares of common stock of the Issuer originally reported as restricted stock. Pursuant to the Merger Agreement, these performance-based restricted stock units were fully accelerated assuming target level of performance immediately prior to the effectiveness of the merger. Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $120.00 per share of common stock of the Issuer on the effective date of the merger. /s/ Catherine Grassman For: Anthony Providenti 2023-06-13